AKT-IN-3

Cat. No.: HY-126257

CAS No.: 2374740-21-1

Molecular Formula: $C_{23}H_{23}Cl_2F_2N_5O_3$

Molecular Weight: 526.36

Target: Akt; Apoptosis

Pathway: PI3K/Akt/mTOR; Apoptosis

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (189.98 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.8998 mL	9.4992 mL	18.9984 mL
5 mM	0.3800 mL	1.8998 mL	3.7997 mL
10 mM	0.1900 mL	0.9499 mL	1.8998 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

AKT-IN-3 (compound E22) is a potent, orally active low hERG blocking Akt inhibitor, with 1.4 nM, 1.2 nM and 1.7 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-3 (compound E22) also exhibits good inhibitory activity against other AGC family kinases, such as PKA, PKC, ROCK1, RSK1, P70S6K, and SGK. AKT-IN-3 (compound E22) induces apoptosis and inhibits metastasis of cancer cells[1].

IC_{50} & Target

Akt1 1.4 nM (IC_{50})	Akt2 1.2 nM (IC_{50})	Akt3 1.7 nM (IC_{50})	PKA 0.3 nM (IC_{50})
P70S6K 8.9 (IC_{50})			

REFERENCES

[1]. Dong X, et al. Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design. J Med Chem. 2019 Aug 8;62(15):7264-7288.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA